Aridis Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Aridis Pharmaceuticals şirketinin toplam hissedar öz sermayesi $-11.8M ve toplam borcu $3.4M olup, bu da borç-öz sermaye oranını -28.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $6.5M ve $18.3M dir.

Anahtar bilgiler

-28.9%

Borç/özkaynak oranı

US$3.41m

Borç

Faiz karşılama oranı	n/a
Nakit	US$35.00k
Eşitlik	-US$11.80m
Toplam yükümlülükler	US$18.34m
Toplam varlıklar	US$6.53m

Son finansal sağlık güncellemeleri

Recent updates

Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%

Sep 26

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

Aug 16

Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

Feb 17

Aridis Pharmaceuticals EPS misses by $0.02

Nov 20

Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

Oct 31

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ARDS negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: ARDS şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ARDS negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: ARDS 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ARDS şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: ARDS tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Aridis Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nasdaq To File A Form 25 with the Securities and Exchange Commission to Complete the Delisting Common Stock of Aridis Pharmaceuticals

Aridis Pharmaceuticals Common Stock to Delist from Nasdaq Capital Market on July 19

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Aridis Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Recent updates

Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments

Aridis Pharmaceuticals, Inc., Annual General Meeting, Dec 15, 2023

Nasdaq To File A Form 25 with the Securities and Exchange Commission to Complete the Delisting Common Stock of Aridis Pharmaceuticals

Aridis Pharmaceuticals Common Stock to Delist from Nasdaq Capital Market on July 19

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Price target decreased by 43% to US$6.00

Insufficient new directors

Aridis Pharmaceuticals, Inc. Announces Top-Line Results from the AR-301-002 Phase 3 Study

Aridis Pharmaceuticals, Inc. Announces New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

Aridis Pharmaceuticals, Inc. announced that it has received $4.848271 million in funding from Cystic Fibrosis Foundation

Aridis Announces A Key Milestone of Closing of Patient Enrollment in the Phase 2A Study of AR-501 in Cystic Fibrosis Patients

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Insufficient new directors

Aridis Pharmaceuticals, Inc. announced that it has received $8 million in funding

Aridis Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

Aridis Pharmaceuticals, Inc. Announces its Inhaled Treatment of its Fully Human Monoclonal Antibody Cocktail AR-701 Resulted in No Detectable SARS-CoV-2 Virus in the Lungs of Infected Rhesus Macaques, and Protected Their Lungs from Disease

Insufficient new directors

Insufficient new directors

Price target decreased to US$9.67

No longer forecast to breakeven

Aridis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Aridis Pharmaceuticals Receives Written Notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Minimum Market Value Requirement

Aridis Pharmaceuticals, Inc. announced delayed annual 10-K filing

Aridis Pharmaceuticals, Inc. Provides Update on its Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 in COVID-19 Omicron Infected Animals

Aridis Pharmaceuticals, Inc. Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

No longer forecast to breakeven

Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses

Consensus revenue estimates fall by 20%

Price target decreased to US$15.00

Price target increased to US$19.00

Aridis Pharmaceuticals, Inc. Announces Covid mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant

Chief Financial Officer Michael Nazak has left the company

Consensus forecasts updated

Consensus forecasts updated

Aridis Pharmaceuticals, Inc. Enters into Out-Licensing and Product Discovery Agreement with Kermode Biotechnologies, Inc

Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of A Second Inhaled Antibody to Neutralize Newly Emerging Covid-19 Mutated Variants

Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

New 90-day high: US$8.08

Aridis Pharmaceuticals EPS misses by $0.02

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

New 90-day low: US$6.38

New 90-day high: US$8.01

Aridis Pharmaceuticals, Inc. to Present At the H.C. Wainwright 21 Annual Global Investment Conference on September 10, 2019

Analysts increase revenue estimates to US$1.63m

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin